High-grade serous ovarian carcinoma (HGSOC)
High-grade serous ovarian carcinoma is the most common and most lethal type of ovarian cancer; it actually starts in the fallopian tube and almost always has a broken TP53 gene.
About 70% of ovarian cancer deaths. Near-universal TP53 mutation, ~50% homologous recombination deficiency (including ~20% BRCA1/2), extensive copy-number instability, few recurrent targetable mutations. Arises from serous tubal intraepithelial carcinoma, which is why opportunistic salpingectomy prevents it. PARP inhibitors, platinum, and FRα ADCs are the main therapeutic levers.
Pages like this
not linked directly; found by shared links- TermCA-125
Shares Ovarian Cancer Research Alliance (OCRA), Ovarian cancer.
- PersonSabine Linn
Shares Homologous recombination deficiency (HRD), BRCA1 / BRCA2 (HRD).
- IdeaA functional test for homologous recombination deficiency validated across laboratories
Shares Homologous recombination deficiency (HRD), BRCA1 / BRCA2 (HRD), Ovarian cancer.
- PersonAngelina Jolie
Shares Risk-reducing and opportunistic salpingectomy, BRCA1 / BRCA2 (HRD), Ovarian cancer.
- TrialPAOLA-1 / ENGOT-ov25
Shares Homologous recombination deficiency (HRD), BRCA1 / BRCA2 (HRD), Ovarian cancer.
- ProductPafolacianine
Shares Folate receptor alpha, Ovarian cancer.
- ProductRucaparib
Shares Homologous recombination deficiency (HRD), BRCA1 / BRCA2 (HRD), Ovarian cancer.
- IdeaGo back to families of women who died of ovarian cancer and offer BRCA testing
Shares BRCA1 / BRCA2 (HRD), Ovarian cancer.